Pharmacotherapy In Pschiatry.docx

  • Uploaded by: ygfhdg
  • 0
  • 0
  • May 2020
  • PDF

This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA


Overview

Download & View Pharmacotherapy In Pschiatry.docx as PDF for free.

More details

  • Words: 810
  • Pages: 8
PHARMACOTHERAPY IN PSCHIATRY 

DEPRESSION



SCHIZOPHRENIA



BIPOLAR DISORDERS

SCHIZOPHRENIA ETHIOLOGY Exact etiology unknown Genetic predisposition Intrauterine, birth or postnatal complications Viral CNS infections Environmental stressors (biochemical or social) No evidence of association with poor parenting

POSITIVE SYMPTOMS

NEGATIVE SYMPTOMS

Hallucination

Social withdrawal

Delusions

Emotional withdrawal

Disordered thinking

Lack of motivation

Disorder speech

Poverty of speech

Combativeness

Blunted affect

Agitation

Poor insight

Paranoia

Poor judgement Poor self-care

ANTIPSYCHOTICS 

Typical/conventional antipsychotics



Atypical antipsychotics

TYPICAL/ CONVENTIONAL ANTIPSYCHOTICS 

Chlorphomazine (Largactic)



Sulpiride (Dogmatil)



Haloperidol (Serenace, Haldol)



Thioridazine (Melleril)



Flupenthixol (Fluanxol)



Trifluoperazine (Stelazine)



Pericyazine (Neulactil)



Thiothixene (Navane)



Pimozide (Orap, Orap Forte)

also known as 

“dopamine receptor antagonist”

-pharmacologic activity at blocking central dopamine receptors (esp. D2 receptors) 

“neuroleptics” -due to tendency to cause neurologic adverse effects



“major tranquilizers”

-inappropriate as these agents (esp. high potency) can improve psychosis without sedating or making patients tranquil

Mechanism of action 

Blocks receptors for dopamine, acetylcholine, histamine and noreepinephrine



Current theory suggests Dopamine2 (D2) receptors suppresses psychotic symptoms 

All typical antipsychotics block D2 receptors



Close correlation between clinical potency and potency as D2 receptor antagonists

Adverse effects 

Extrapyramidal symptoms (EPS) 

Early reactions- can be managed with ddrugs  Acute dystonia  Parkinsonism  Akathsiia



Late reaction - drug treatment unsatisfactory 

Tardive dyskinesia



Early reactions occur less frequently with low potency drugs



Risk od TD is equal with all agents

ATYPICAL ANTIPSYCHOTICS 

Refers to new agents



Also known as





“Serotonin-dopamine antagonists”



Postsynaptic effects at 5-HT2A and D2 receptors

Amisulpiride (Solian)



Quetiapine (Seroquel)



Ziprasidone (Zeldox)



Clozapine (Clozaril)



Risperidone (Risperdal)



Aripiprazole (Abilify)



Olanzapine (Zyprexa)

Clozapine 



Contraindication 

History of clozapine-induced agranulocytosis



Bone marrow suppression



On myelosuppressive drugs

Caution 

Seizure disorders



Diabetes

NON-ANTIPSYCHOTIC AGENTS Benzodiazepines 

Useful in some studies for anxiety, agitation, global impairment and psychosis



Schizophrenic patients are prone to BZD abuse



Limit use shorts trials (2-4 weeks) for management of severe agitation and anxiety

Lithium 

Limited role in schhizophrenia monotherapy



Improve psychosis, depression, excitement and irritability when used with antipsychotic in some studies.

DEPRESSION 

Depressed mood and/or decrease in interest in things that used to give pleasure



Sadness severe enough or persistent enough to interfere with funtion



DSM-IV 

Major depressive disorder / major depression



Dysthymia



depressive for most of the day, more days than not



Depressive disorder not otherwise specified



Depressive disorder due to a general physical condition



Substance-induced depressive disorder

Epidemiology 

Life prevalence 3-17%



Onset in late 20s



Highest in





25-44 years



Elderly in community

Female vs Male = 2:1 

Female 10-20% lifetime risk



Male 5-12% lifetime risk

Signs and symptoms 

Depressed mood



Concentration loss



Sleep (insomia or hypersomnia)



Appetite (loss or gain)



Loss of interest (including libido)





Guilt

Psychomotor (agitation or retardation)



Energy loss



Suicide (ideation)

Pathophysiology 

Exact course unknown 

Change in receptor-neurotransmitter relationship in limbic system 



Serotonin, norepinephrine, somtimes dopamine

Increased pump uptake of neurotransmitters 

Reabsorption into neuron



Destroyed by monoamine oxidase in mitochondria



Lack of neurotransmitters

Antidepressants 

Tricyclic and related antidepressants (TCA) e.g. amitriptyline, imipramine, doxepin, mianserin, trazodone



Monoamine-oxidase inhibitors (MAOI) e.g. moclobemide, phenelzine, isocarboxazid, tranylcypromine



Selective serotonin reuptake inhibitors (SSRI) e.g. fluoxetine, paraxetine, sertraline, citalopram



Other antidepressants e. mirtazapine, venlafaxine, duloxetine, flupentixol

Tricyclic and related antidepressants (TCA) 

Amitriptyline (Saroten)



Mianserin (Tolvon)



Clomipramine (Anafranil)



Nortriptyline (Nortrilen)



Dothiepin (a.k.a. Dosulepin, Prothiaden)



Trazodone (Trittico)



Trimipramine (Surmontil)



Imipramine (Tofranil)

Mechanism of action 

Blocks neuronal uptake or norepinephrine and serotonin



Initial response develops in 1-3 weeks



Maximal response develops in 1-2 months



Older tricyclic





Marked anticholinergic adversse effects



Risk of carditoxicity

Tricyclic-related drugs (e.g. trazodone) 

Fewer anticholinergic adverse effects



Sedation, dizziness, priapism (persistent penile erection accompanied by pain and tenderness)

Properties 

Inexpensive, generic



Some with off-label use, e.g.





Neuropathy with amitriptyline



Refractory skin diseases with doxepin

Very dangerous in overdose 

Life threatening



Lethal dose only 8 times average daily dose



Acutely depressed patients should not be given more than 1-week TCA supply at one time

Monoamine-oxidase inhibitors (MAOI) Properties 

Useful in atypical depression (somnolence and weight gain), refractory disorder and certain types of anxiety disorders



Less prescribed than tricyclics, SSRIs and other antidepressants 

Danger of dietary and drug interactions

Adverse effects 

Hypertensive crisis  Severe occipital headache, photophobia, palpitation, sharply increased in BP due to addictive effect between MAOI and adrenergic stimulants  Tyramine-rich food e.g. cheese, wine, smoked/aged picked meat or fish, alcohol  Amphetamine  Pseudoephedrine

Related Documents


More Documents from "syclik"